MIT chemical engineers have developed a new type of lipid nanoparticle that can be used to deliver RNA vaccines. The particles also trigger the release of powerful immune signaling proteins that boost the vaccines' effectiveness.
Read moreWhole genome sequencing of tumour cells could help predict the prognosis of a patient's cancer and offer clues to identify the most effective treatment, suggests an international study.
Read moreAn age-related decline in recovery from muscle injury can be traced to a protein that suppresses the special ability of muscle stem cells to build new muscles, according to new work.
Read moreA new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.
Read moreAnti-epileptic medicine can curb the dangerous communication and possibly be part of future treatment.
Read moreAdolescent acne does not always result in a pathological condition; rather, it may be a natural, transient inflammatory state occurring when the maturing facial skin is exposed to new microbes and enhanced production of an oily substance called sebum. Researchers argue that their novel framework suggests that the development of new treatments should focus on promoting mechanisms that restore homeostasis between facial skin and its microbial and chemical milieu.
Read moreA new discovery about pancreatic cancer sheds light on how the cancer fuels its growth and may help explain how promising cancer drugs work — and for whom they will fail.
Read moreScientists have discovered how temporal fluctuations in the levels of two transcription factors can push embryonic stems cells into becoming different cell types.
Read moreInvestigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase 1B study.
Read moreA metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists.
Read more